Publication: Dissecting the role of aberrant DNA methylation in human leukemia
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Amabile, G., A. Di Ruscio, F. Müller, R. S. Welner, H. Yang, A. K. Ebralidze, H. Zhang, et al. 2015. “Dissecting the role of aberrant DNA methylation in human leukemia.” Nature communications 6 (1): 7091. doi:10.1038/ncomms8091. http://dx.doi.org/10.1038/ncomms8091.
Research Data
Abstract
Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder characterized by the genetic translocation t(9;22)(q34;q11.2) encoding for the BCR-ABL fusion oncogene. However, many molecular mechanisms of the disease progression still remain poorly understood. A growing body of evidence suggests that epigenetic abnormalities are involved in tyrosine kinase resistance in CML, leading to leukemic clone escape and disease propagation. Here we show that, by applying cellular reprogramming to primary CML cells, aberrant DNA methylation contributes to the disease evolution. Importantly, using a BCR-ABL inducible murine model, we demonstrate that a single oncogenic lesion triggers DNA methylation changes which in turn act as a precipitating event in leukemia progression.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service